EUVIMEDEUVIMED entdecken
Crossref

The serum LDH level and KELIM scores are potential predictors of a benefit from bevacizumab first-line therapy for patients with advanced ovarian cancer

Yi Liu, Lin Yuan, Zhang Lin, Miao Huixian, Meng Huangyang, Wenjun Cheng

Clinical and Translational Oncology · 21.06.2024 · 27 (1) · 340-350

DOI: 10.1007/s12094-024-03569-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Oncology, online erschienen am 21.06.2024. Verfasst von Yi Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Nanjing, 210029, Jiangsu, China. Hauptthemen laut MEDLINE: Bevacizumab, Ovarian Neoplasms, L-Lactate Dehydrogenase, Biomarkers, Tumor. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation, Natural Science Fund of Jiangsu Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: The survival benefit of first-line treatment with bevacizumab in advanced ovarian cancer patients are multifaceted. In our study, we aimed to identify potential markers of bevacizumab efficacy to help predict which patients would experience survival benefits. METHODS: This was a retrospective analysis of 114 patients examined from January 1, 2015, to March 1, 2023, and data on clinical, biological, and imaging variables, such as ascites, serum LDH, and CA125, were extracted from electronic medical records. We performed a correlation analysis and principal component analysis to investigate correlations among variables and reduce their dimensionality. Then, univariate and multivariate Cox proportional hazards regression analyses were used to identify the predictors of progression-free survival. RESULTS: Favorable KELIM score (≥ 1, HR 0.376, 95% CI [0.202-0.700], p = 0.002), which indicated better chemosensitivity, and lower LDH levels (≤ 210 U/L, HR 38.73, 95% CI [6.108-245.6], p < 0.001) were found to be independent predictors of a treatment benefit with bevacizumab in patients with advanced ovarian cancer. Regardless of LDH level, patients with favorable KELIM scores had a higher progression-free survival (PFS) benefit (p = 0.18). Among patients with unfavorable KELIM scores, those with higher LDH levels had the lowest PFS benefit (median: 11.5 months, p = 0.0059). CONCLUSION: Patients with poor chemosensitivity and low LDH levels are more likely to benefit from first-line bevacizumab treatment. The combination of the two markers can be a helpful predictor of patients who are most likely to benefit from treatment and a guide for treatment decisions-making. Retrospectively registered: 2020-MD-371, 2020.10.12.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BevacizumabOvarian NeoplasmsL-Lactate DehydrogenaseBiomarkers, TumorAntineoplastic Agents, ImmunologicalHumansFemaleRetrospective StudiesMiddle AgedAgedProgression-Free SurvivalAdultCA-125 AntigenPrognosisAged, 80 and over

Stichwörter der Autor:innen

BevacizumabBiomarkersKELIMLDHOvarian cancer

Substanzen

BevacizumabL-Lactate DehydrogenaseBiomarkers, TumorAntineoplastic Agents, ImmunologicalCA-125 Antigen

Autor:innen und Institutionen

  • Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Nanjing, 210029, Jiangsu, China.
  • Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Nanjing, 210029, Jiangsu, China. wenjunchengdoc@163.com.

Förderung

  • National Natural Science Foundation of China
  • China Postdoctoral Science Foundation
  • Natural Science Fund of Jiangsu Province
  • Jiangsu Province Traditional Chinese Medicine Science and Technology Development Plan Project-Key Project
  • General Project of Yili Clinical Medical Research Institute
  • Jiangsu Provincial Maternal and Child Health Research Fund

Zitieren

APA

Liu, Y., Yuan, L., Lin, Z., Huixian, M., Huangyang, M., & Cheng, W. (2024). The serum LDH level and KELIM scores are potential predictors of a benefit from bevacizumab first-line therapy for patients with advanced ovarian cancer. Clinical and Translational Oncology, 27(1), 340-350. https://doi.org/10.1007/s12094-024-03569-3

Vancouver

Liu Y, Yuan L, Lin Z, Huixian M, Huangyang M, Cheng W. The serum LDH level and KELIM scores are potential predictors of a benefit from bevacizumab first-line therapy for patients with advanced ovarian cancer. Clinical and Translational Oncology. 2024;27(1):340-350. doi:10.1007/s12094-024-03569-3

BibTeX
@article{Liu2024,
  author = {Liu, Yi and Yuan, Lin and Lin, Zhang and Huixian, Miao and Huangyang, Meng and Cheng, Wenjun},
  title = {The serum LDH level and KELIM scores are potential predictors of a benefit from bevacizumab first-line therapy for patients with advanced ovarian cancer},
  journal = {Clinical and Translational Oncology},
  year = {2024},
  volume = {27},
  number = {1},
  pages = {340--350},
  doi = {10.1007/s12094-024-03569-3}
}
Kostenlos starten →